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INTRODUCTION
Since 1996, international conferences on hematopoietic
stem cell transplantation (HSCT) in autoimmune diseases
have been held every 2 years in Basel, Switzerland, under
sponsorship of the European Group for Blood and Marrow
Transplantation (EBMT) and the European League against
Rheumatism (EULAR). As phase I-II studies matured with
longer follow-up, the advantage of a meeting in 2001 became
apparent, and the EBMT along with the American Society
for Blood and Marrow Transplantation (ASBMT) and
the Autologous Blood and Marrow Transplant Registry
(ABMTR) agreed to cosponsor a meeting in the United
States. This conference, Hematopoietic Stem Cell Therapy
in Autoimmune Diseases, was held October 4-5, 2001, at the
City of Hope National Medical Center in Duarte, California.
The morning sessions were devoted to the topics of
immunological tolerance, experimental autoimmunity,
and stem cell biology. Speakers included John DiPersio
(St. Louis), Garrison Fathman (Palo Alto), Robert Korngold
(Philadelphia), Nora Sarvetnick (La Jolla), Judith Shizuru
(Palo Alto), and Kenneth Weinberg (Los Angeles). Richard
Burt (Chicago) gave a general talk on future directions of
HSCT in autoimmune diseases, and Peter McSweeney
(Denver) discussed the potential of nonmyeloablative allo-
geneic transplantation for autoimmune diseases. Most of the
afternoon clinical presentations at the meeting concerned
phase I-II feasibility studies of autologous HSCT in autoim-
mune diseases. Recent reviews have presented the rationale
and current results of this treatment [1,2]. Rather than pre-
senting detailed results, this synopsis summarizes major
points of discussion of the clinical sessions. Also summarized
here are the sessions on ethical and regulatory aspects of
HSCT in autoimmune diseases.
MULTIPLE SCLEROSIS 
The multiple sclerosis (MS) session began with an
introduction to the rationale of high-dose immunosup-
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ABSTRACT
Since 1996, patients with autoimmune diseases have been treated on single-arm investigational protocols with high-
dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation (HSCT). In a confer-
ence held in October 2001 at the City of Hope National Medical Center, participants discussed current laboratory
studies in autoimmunity, the rationale of HSCT in autoimmune diseases, results of phase I-II studies, and the
prospects for controlled trials. This conference synopsis summarizes major discussion points in clinical sessions and
in sessions devoted to ethical and regulatory aspects of this investigational treatment. Protocols for controlled stud-
ies in multiple sclerosis (MS) and systemic sclerosis (SSc), originating in Europe and in the United States, have been
designed or are in the final stages of design. The only controlled trial presently underway is for SSc in Europe
(Autologous Stem Cell Transplantation International Scleroderma Trial [ASTIS]). There are current plans for a
controlled trial for rheumatoid arthritis (RA) in Europe (ASTIRA) but not in the United States. Eventual cross-
study analysis of the European and United States trials may give valuable comparative information on the different
mobilization and immunosuppressive regimens used. Recognition of the importance of axonal degeneration in sec-
ondary progressive MS and the use of mitoxantrone as a rescue medication are two relatively recent developments
now being considered in the design of controlled HSCT protocols in MS. The importance of informed consent and
study accessibility was discussed as well as the continuing role of the US Food and Drug Administration in regulat-
ing these protocols in the United States.
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pression with HSCT, presented by Jerry Wolinsky (Hous-
ton). This presentation was followed by four reports of
clinical results: Athanasios Fassas (Thessaloniki) on the
first 85 patients reported to the European (EBMT) reg-
istry, Bruce Cohen (Chicago) on 27 patients treated on the
Northwestern/ Medical College of Wisconsin protocol,
Richard Nash (Seattle) on 26 patients treated by the Seat-
tle group on the protocol originating at Fred Hutchinson
Cancer Research Center, and Gianluigi Mancardi (Genoa)
on 16 Italian patients followed closely by monthly mag-
netic resonance imaging (MRI) scans. A detailed report on
the first 85 MS patients reported to the EBMT registry is
in press [3], and abstracts by the Northwestern, Seattle,
and Italian groups have been published subsequent to the
meeting [4-6]. Following the clinical presentations, there
was a panel discussion that included the presenters along
with Donald Paty (Vancouver) and Leslie Weiner (Los
Angeles).
Controlled trials are planned both in Europe and in the
United States. Drs. Mancardi and Nash presented some
details on these planned studies (with the caveat that the
protocols for both studies were still in draft form and agree-
ment of all principal investigators involved in protocol
designs had not yet been obtained). The studies will proba-
bly be similar in terms of criteria for patient eligibility,
including Expanded Disability Status Scale (EDSS) scores
of 3.5 to 6.0 or 6.5 and probable requirement of docu-
mented recent gadolinium enhancement; use of mitox-
antrone in the control arm; and population size require-
ment of 200 or more subjects. Differences in the studies
include mobilization and preparatory regimens: granulo-
cyte colony-stimulating factor (G-CSF) plus cyclophos-
phamide and BEAM (BCNU, etoposide, cytosine arabi-
noside, and melphalan) with antithymocyte globulin (ATG)
in the European study versus G-CSF plus prednisone and
total body irradiation (TBI) plus cyclophosphamide and
ATG in the United States study. The United States study
will use autologous grafts T-cell depleted by CD34 cell
selection. The potential for cross-study comparisons, partic-
ularly of the preparatory regimens, was briefly discussed.
Comparisons could reasonably be done if the entrance
requirements and methods of evaluation were sufficiently
similar in the ﬁnal design of these studies. Mark Freedman
(Ottawa) presented a brief report on the recently initiated
Canadian phase II study of 24 patients (EDSS score, 3.0-
6.0) receiving busulfan and cyclophosphamide conditioning
and a doubly T-cell–depleted graft. Patients followed in this
study will undergo tests with a panel of immunological
assays, including assays with speciﬁc myelin antigens.
During Dr. Wolinsky’s introduction and the concluding
panel discussion, there was discussion of newer develop-
ments in understanding MS that have changed the way
many neurologists view HSCT now compared to 4 to 5
years ago when the first feasibility studies were initiated.
Although there has been evidence for many years of an
axonal degenerative process in MS, the importance of this
process in terms of progression at the higher EDSS levels
has only recently been fully appreciated. Dr. Wolinsky
showed an example of progressive destruction of myelin
matrix, visible on MRI scans in the absence of gadolinium
enhancement, as evidence supporting the likelihood of clini-
cal progression in the absence of an ongoing systemically
initiated inﬂammatory process. Of course, HSCT may not
address this late-evolving noninflammatory aspect of MS.
The most appropriate patients for HSCT may be those at
lower EDSS levels, at which the inﬂammatory component
of the disease is most active. Unfortunately, of the patients
previously treated in feasibility studies, relatively few were
at the lower EDSS levels. Also, the view was expressed that
the lower the patient score on the EDSS scale, the lower
the transplantation-related morbidity and mortality would
have to be for an acceptable protocol. Another recent
change in MS therapy is the concept of rescue medication
(ie, for those patients worsening on the immunomodulaters
β-interferon or glatiramer acetate) and the availability of a
US Food and Drug Administration (FDA)-approved rescue
medication, mitoxantrone (generally given at 12 mg/m2
every 3 months for 2 years). As presently used, HSCT itself
would be considered a rescue treatment, and thus compari-
son of its effectiveness with that of mitoxantrone, as
intended in the planned controlled trials, is appropriate.
However, it was pointed out that patients who had under-
gone prior mitoxantrone treatment would have to be
excluded from HSCT studies because mitoxantrone would
be the control arm and there is a limitation on the total
dose of mitoxantrone because of cardiac toxicity. This
exclusion will make recruitment to the HSCT control trials
more difﬁcult, especially with the number of investigational
studies now adding mitoxantrone to immunomodulaters.
Finally, the study that led to FDA approval of mitoxantrone
for MS (as yet unpublished but available on the FDA Web
site) reported a very good response in patient participants
during 2 years of treatment and 1 year of follow-up. There
are no plans for a repeat study of mitoxantrone; the planned
controlled HSCT trials in Europe and the United States
may provide the best data to replicate the mitoxantrone
results on the FDA Web site.
At the onset of this session, Dr. Wolinsky set out what
hurdles, in his opinion, are to be cleared in order for
HSCT to be an acceptable therapy for MS. These include
a reduction in morbidity and mortality from the initial
open-label trials, elimination of central nervous system
inflammation, and elimination of the matrix destructive
phase of the disease. In addition, for its equivalency to
mitoxantrone to be established, HSCT would have to
decrease attack frequency at least 70% and decrease sus-
tained EDSS score progression of 1.0 point to 8% of
patients at 2 years and 17% at 3 years after HSCT. Few
investigators expect mitoxantrone to sustain effectiveness
for more than a few years after it is discontinued. There-
fore, it will be important for HSCT to have a durable
response that stretches well beyond 3 years. The consensus
among specialists is that little will be achieved with addi-
tional single-arm studies. Controlled trials against mitox-
antrone are needed with evaluators blinded to the subjects’
treatment group. It will be important for these studies to
incorporate early stopping rules for excessive toxicity and
differences in early progression. Studies as long as 5 years
(ie, 3 years after subjects on the nontransplantation arm
complete mitoxantrone) will probably be necessary because
the advantage of HSCT over mitoxantrone may be in the
durability of the response.
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RHEUMATOLOGICAL DISEASES 
Ken Kalunian (Los Angeles) reviewed eligibility criteria
and results on systemic lupus erythematosus (SLE) patients
reported by Traynor [7]. Robert Brodsky (Baltimore) sent an
abstract updating results of high-dose cyclophosphamide
without autografts in autoimmune diseases [8].
Rheumatologist Walter Barr (Chicago) presented an
overview of systemic sclerosis (SSc). This overview was fol-
lowed by a presentation by J. M. van Laar (Leiden, The
Netherlands) of the recently opened (March 2001) Euro-
pean SSc trial (Autologous Stem Cell Transplantation Inter-
national Scleroderma Trial [ASTIS]) and a review by Keith
Sullivan (Durham) of patients treated in the United States
on the Seattle consortium protocol [9]. An abstract provided
for the meeting by Alan Tyndall (Basel) noted 72 SSc
patients have been reported to the EBMT registry. A report
on the ﬁrst 45 SSc registry patients has been published [10].
Data now available on 65 registry patients indicate that
these patients have a transplantation-related mortality of
12.5%, decreased from 17% in the ﬁrst 45 registry patients.
Treatments used in the ASTIS trial included cyclophos-
phamide and G-CSF for stem cell mobilization and cyclo-
phosphamide (200 mg/kg) plus rabbit ATG (7.5 mg/kg)
for conditioning. In contrast, the Seattle consortium uses
G-CSF without cyclophosphamide for mobilization and 8 Gy
TBI (2 Gy to the lungs), cyclophosphamide (120 mg/kg), and
equine ATG (90 mg/kg) for conditioning [10]. The primary
end point of the ASTIS trial is time to death or development
of persistent heart, lung, or kidney failure within the intended
2-year follow-up period. Treatment for the ASTIS control
group is monthly pulsed cyclophosphamide (750 mg/m2) for
12 months. The control study in the United States (which
will be sponsored by the National Institutes of Health [NIH])
is still under design, but the expectation is that it will use the
Seattle consortium protocol and the same control group
treatment of monthly pulsed cyclophosphamide. Both studies
will enroll SSc patients with poor prognosis indicators with
an anticipated 5-year natural history mortality of 50%. To be
eligible, patients must have a disease duration of <3 years
(Seattle consortium) or <4 years (ASTIS).
Steven Pavletic (Omaha) presented an update on 6 rheuma-
toid arthritis (RA) patients treated at Northwestern and
Omaha. These patients were initially described in 1999 [11],
and now are at 24- to 42-month follow-up. Most patients
achieved a major response, according to American College of
Rheumatology (ACR) criteria, of 70% to 80% for 6 to
22 months, and after relapse there was a greater tendency to
respond to disease-modifying antirheumatoid drugs than
before HSCT [12]. Dr. Paul Emery’s abstract (Leeds, UK)
introduced the planned ASTIRA (Autologous Stemcell
Transplantation International Rheumatoid Arthritis) study.
This will be a randomized study, under the auspices of
EBMT/EULAR, enrolling patients with severe active disease
who have had documented failure of methotrexate and/or
leﬂunomide as well as failure of anti-TNFα treatment. The
HSCT arm will use unmanipulated grafts, cyclophos-
phamide, G-CSF mobilization, cyclophosphamide condi-
tioning (200 mg/kg), and posttransplantion maintenance
therapy of methotrexate or leﬂunomide, whereas the non-
HSCT arm will use conventional therapy of methotrexate or
leﬂunomide alone. All subjects enrolled will undergo stem
cell collection prior to randomization. The primary end
point will be disease activity at 6 months postrandomization,
and patients in the nontransplantation arm may proceed to
HSCT at this point if the response is inadequate.
Nico Wulffraat (Utrecht) presented an update on the
European transplantation results for juvenile idiopathic arthri-
tis (JIA). Twenty-three patients from 4 centers in the Nether-
lands, Germany, and Belgium have been registered to the
EBMT database. For JIA treatment most patients received
low-dose TBI (4 Gy) and cyclophosphamide (50 mg/kg per
day for 4 days) along with ATG in the preparatory regimen.
However, 7 patients undergoing transplantation in Belgium
and Germany had cyclophosphamide and ATG without TBI,
and all 7 achieved drug-free remission for more than a year.
There are concerns of growth inhibition by TBI, but children
who achieved remissions with TBI conditioning in Utrecht
had impressive growth spurts of 1 to 4 standard deviations.
Future studies should assess the need for TBI in the prepara-
tory regimen and the necessity of T-cell depletion of the graft.
The regimen used for 18 patients in Utrecht induced a severe
CD4 lymphopenia lasting 6 to 12 months and resulted in mul-
tiple infectious complications: 10 varicella-zoster virus infec-
tions, 2 septicemias, 1 atypical mycobacterial infection, and
1 Epstein-Barr virus reactivation.
ETHICAL AND REGULATORY ASPECTS 
HSCT treatment for autoimmune diseases raises several
ethical and regulatory issues. David Snyder (Duarte), chair
of the ethics committee at the City of Hope National
Medical Center, discussed the importance of patient auton-
omy in making informed decisions. He stressed that an
understanding of the potential risks and benefits of this
novel therapy is particularly important in illnesses that are
non–life-threatening although potentially associated with
signiﬁcant morbidity. With this concept as the central theme,
Dr. Synder reviewed other speciﬁc issues in designing clini-
cal trials in autoimmune disease. The acute leukemia histori-
cal model of ﬁrst treating patients at a very late disease stage
is likely not to be helpful in treating autoimmune disease, Dr.
Snyder noted, because patients with late-stage autoimmune
disease, particularly MS, may not benefit; patients with
reversible but high-risk disease should be identiﬁed. He also
emphasized the importance of phase III trials as well as the
difficulty in performing them because of the difficulty in
guarding against patients’ preconceptions, which generally
favor the new therapy. The last issue on this topic was that of
“justice,” ie, balancing interests in new therapies with the
appropriate use of limited resources. How should these trials
be funded? Do third-party payers have an obligation to
underwrite these trials? Such a position is arguable because
insurance companies are potential benefactors of decreased
long-term health care costs if these therapies are demon-
strated efﬁcacious in preventing disability.
In a second session, Mary Horowitz (Milwaukee) inter-
viewed Jeffrey Siegel (Rockville) on the role of the FDA in
regulating trials of HSCT for autoimmune disease in the
United States. Dr. Siegel is a clinical reviewer in the Division
of Clinical Trials at the Center for Biologics at the FDA and
is the principal rheumatologist reviewing development of
biologic therapeutics. He is chair of the FDA Rheumatology
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Focus Group and serves as clinical reviewer for many of the
Investigational New Drug applications (INDs) for HSCT.
Dr. Horowitz first asked why the FDA has become
involved in regulating devices and drugs that are regularly
used (without IND) in HSCT for malignancies. Dr. Siegel
explained that in many instances these devices and drugs are
approved, but not for treating autoimmune disease.
Although the FDA does not in general regulate the practice
of medicine, ie, off-label use of many approved drugs, it does
have an important role in regulating use of products for new
indications when there are significant safety concerns.
Because HSCT carries substantial risk of early treatment-
related mortality, its use in autoimmune diseases, in which
early mortality is unusual, warrants careful scrutiny and reg-
ulation, ie, procedures to obtain proof of safety and efﬁcacy.
Dr. Siegel also commented that there is FDA regulation of
HSCT just as there is FDA regulation of blood banking and
blood products. The level of regulation depends on the level
of concern regarding transmission of communicable disease,
processing, and clinical safety and efficacy. Detailed FDA
regulations regarding use of other than manipulated hemato-
poietic stem cells for nonhomologous uses are in ﬁnal stages
of preparation.
Dr. Horowitz asked about the perceived pressure from
the FDA for randomized study designs (phase III studies) in
evaluating the use of HSCT in treating autoimmune dis-
eases, despite limited phase II data in this setting. Dr. Siegel
commented that the push for randomized studies comes out
of concerns that HSCT can be highly toxic and its beneﬁts
are not yet proven to outweigh its risks. Faced with a rapidly
increasing number of uncontrolled studies, the FDA felt
that data to address this risk versus beneﬁt question would
not be forthcoming in a timely manner. However, Dr. Siegel
agreed that in some (but not all) diseases, the data are not
sufﬁcient to adequately plan large phase III trials and that
there is a role for moderately sized randomized phase II tri-
als to estimate effect sizes and learn more about the appro-
priate HSCT regimens to take to phase III trials. Dr. Siegel
pointed out that many pharmaceutical trials randomize even
at the phase I level so that risk/benefit ratio can be more
accurately and efﬁciently estimated.
In response to a question as to what would constitute
adequate control groups and control therapies, Dr. Siegel
said that for many studies the control group would not have
to receive a single strictly controlled non-HSCT regimen
but, rather, could be randomized to “standard of care” or
some other non-HSCT experimental treatment. If a pri-
mary end point for the study could be chosen that demon-
strated success or failure in a reasonable time frame, patients
failing to respond to therapy in the control group could be
offered HSCT. On the other hand, if it is possible to iden-
tify a patient population that has a uniformly poor outcome
(high mortality) with standard therapy, a nonrandomized
design might be acceptable. Getting agreement on patient
characteristics that deﬁne such a group is often difﬁcult in
the diseases under consideration—and these patients may
not be the ones most likely to beneﬁt from HSCT. In the
absence of defined groups with uniformly poor prognosis,
success or failure of the treatment may be determined to a
large extent by patient selection practices. Control groups
determined by lack of insurance or refusal of the therapy
may be biased. Use of disease-based databases with detailed
patient data may be acceptable in some instances for evalua-
tion of phases I or II level data.
FDA-regulated studies carry a high burden of reporting
requirements for adverse events. Dr. Horowitz commented
that HSCT is an aggressive therapy for which certain
adverse events are expected, eg, febrile neutropenia, platelet
transfusion requirement, intravenous catheter infections.
Dr. Siegel stated that adverse events must indeed be
recorded and reported, although expedited reporting, which
is the most burdensome, is required only for unexpected
serious or life-threatening events. If an event is listed as
expected in the investigators’ brochure, it does not need
expedited reporting, and the level of reporting detail
required is less. Dr. Horowitz pointed out that recording
events for reporting, whether immediate or delayed, is time-
consuming and costly even if the events are expected. She
noted that modified requirements for HSCT studies have
been discussed in several forums.
Dr. Horowitz asked about the respective roles of the
NIH and the FDA in reviewing and approving studies. Dr.
Siegel noted that the NIH funds studies, and the studies for
which it provides funding must have NIH approval for the
study design. The FDA makes sure that studies meet regula-
tory standards. The FDA approves studies when patient
safety is adequately protected and the trial is adequately
designed to meet its goals of proving safety and efficacy.
Dr. Siegel suggested that investigators involve the FDA
early in designing studies so that designs unlikely to be
approved on regulatory grounds are not pursued.
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